Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700
Debt
Debt-to-Equity RatioN/A
Current Ratio33.12
Quick Ratio33.12
Price-To-Earnings
Trailing P/E Ratio-21.78
Forward P/E Ratio10.05
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.07 million
Price / Sales672.70
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book6.03
Profitability
EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-3,232.73%
Return on Equity-23.15%
Return on Assets-22.17%
Miscellaneous
Employees18
Outstanding Shares183,620,000
Market Cap$692.26 million
Geron (NASDAQ:GERN) Frequently Asked Questions
What is Geron's stock symbol?
Geron trades on the NASDAQ under the ticker symbol "GERN."
How were Geron's earnings last quarter?
Geron Co. (NASDAQ:GERN) announced its earnings results on Tuesday, July, 31st. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.04). The biopharmaceutical company earned $0.21 million during the quarter, compared to analysts' expectations of $0.21 million. Geron had a negative net margin of 3,232.73% and a negative return on equity of 23.15%. View Geron's Earnings History.
When is Geron's next earnings date?
What price target have analysts set for GERN?
5 brokers have issued twelve-month target prices for Geron's shares. Their predictions range from $4.00 to $7.00. On average, they expect Geron's stock price to reach $5.5833 in the next year. This suggests a possible upside of 42.4% from the stock's current price. View Analyst Price Targets for Geron.
What is the consensus analysts' recommendation for Geron?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.
Are investors shorting Geron?
Geron saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 58,323,015 shares, an increase of 3.2% from the July 13th total of 56,530,838 shares. Based on an average trading volume of 4,071,690 shares, the short-interest ratio is presently 14.3 days. Approximately 33.9% of the company's shares are short sold. View Geron's Current Options Chain.
Who are some of Geron's key competitors?
Some companies that are related to Geron include Emergent Biosolutions (EBS), Mallinckrodt (MNK), Supernus Pharmaceuticals (SUPN), Global Blood Therapeutics (GBT), Myokardia (MYOK), Akorn (AKRX), Spectrum Pharmaceuticals (SPPI), Xencor (XNCR), Cambrex (CBM), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Phibro Animal Health (PAHC), Prestige Brands (PBH), Portola Pharmaceuticals (PTLA) and G1 Therapeutics (GTHX).
Who are Geron's key executives?
Geron's management team includes the folowing people:
- Dr. John A. Scarlett, CEO, Pres & Director (Age 67)
- Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 49)
- Dr. Andrew J. Grethlein, Exec. VP of Devel. & Technical Operations (Age 54)
- Mr. Stephen N. Rosenfield, Exec. VP, Gen. Counsel & Corp. Sec. (Age 68)
- Ms. Melissa A. Kelly Behrs, Exec. VP of Bus. Devel., Portfolio & Alliance Management (Age 54)
Has Geron been receiving favorable news coverage?
News stories about GERN stock have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 48.12 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Geron.
Who are Geron's major shareholders?
Geron's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (8.48%), BlackRock Inc. (7.29%), Bank of America Corp DE (0.68%), Schwab Charles Investment Management Inc. (0.19%), Creative Planning (0.18%) and Rhumbline Advisers (0.08%). View Institutional Ownership Trends for Geron.
Which major investors are selling Geron stock?
Which major investors are buying Geron stock?
GERN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, California Public Employees Retirement System, Creative Planning, Schwab Charles Investment Management Inc., SG Americas Securities LLC, MetLife Investment Advisors LLC and Rhumbline Advisers. View Insider Buying and Selling for Geron.
How do I buy shares of Geron?
Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Geron's stock price today?
One share of GERN stock can currently be purchased for approximately $3.92.
How big of a company is Geron?
Geron has a market capitalization of $692.26 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.
How can I contact Geron?
Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]
MarketBeat Community Rating for Geron (NASDAQ GERN)
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
